350 Capital

“Anthropic trains its models only on $AMZN Trainium” That’s a clickbait story. Not reality. Anthropic runs its models across: $AMZN Trainium, $GOOGL TPUs, and $NVDA GPUs. This hybrid approach is deliberate. Two reasons: 1. $AMZN and $GOOGL both own >10% of Anthropic, and those deals included commitments to heavily use their chips 2. Anthropic doesn’t want to depend on a single supplier This does NOT mean $NVDA is losing its edge. Its chips are still the best. What’s changing is behavior: AI labs don’t want to rely entirely on Nvidia and keep paying a ~10x markup on every chip in their data centers. Implications: • $NVDA will lose some market share, but in a market growing ~60% annually it’s not a real problem • $AMD will capture part of that share

Our Lithium Refinery is designed to have a much lower carbon footprint than traditional hard rock refineries – Acid-free refining helps produce a safe coproduct – Water is recycled throughout production, with every drop treated & cleaned on site – Designed to close the loop for lithium in our battery supply chain

$HIMS Everyone knows Ozempic now. It peaked mid-2024 and became a household name. You can ask almost anyone and they’ll know what it is or at least what it does. Now look at “peptides.” Most people you know have no idea what that even means. Ask someone close to you. They won’t have a clue. But search interest is telling you something very different. It’s accelerating fast and is now approaching where Ozempic was at peak attention. Peptides are short chains of amino acids that influence specific biological pathways. They can target fat loss, muscle growth, recovery, inflammation, and longevity. The scope is broad and still evolving. It is early, fragmented, and not yet understood by the public. Which is exactly why the opportunity exists. That’s where HIMS comes in. They’ve already proven they can take a stigmatized or complex category and make it simple, accessible, and consumer-friendly at scale. They did it with hair loss. They did it with ED. They are doing it with weight loss. When peptides move from niche/black market to mainstream, HIMS is one of the few platforms positioned to capture that demand early and package it for the mass market. You don’t need to guess if people are interested. Search is already telling you. Ozempic is already a household name. Peptides are next.

$PSKY "Paramount" Bullflag forming after our monster 32% Run from bottom. Key important point is waiting the breakout with volume here. Last week Paramount secured 24B $ in equity commitment from middle east to secure the WarnerBros deal

RFK Jr. said the FDA plans to remove 12 peptides from Category 2. Moving peptides out of the gray market and into regulated channels could create a more credible and scalable opportunity for $HIMS.